✦ LIBER ✦

Quantum concept of bone remodeling and turnover: Implications for the pathogenesis of osteoporosis

✍ Scribed by A. M. Parfitt

Publisher: Springer
Year: 1979
Tongue: English
Weight: 445 KB
Volume: 28
Category: Article
ISSN: 1432-0827
DOI: 10.1007/bf02441211

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effects and regulation of prostaglandins

Effects and regulation of prostaglandins in bone: Possible implications for the pathogenesis of osteoporosis

✍ Lawrence G. Raisz; Carol C. Pilbeam; Jenneke Klein-Nulend; John R. Harrison 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 526 KB

Biochemical markers of bone turnover for

Biochemical markers of bone turnover for the clinical investigation of osteoporosis

✍ P. D. Delmas 📂 Article 📅 1993 🏛 Springer-Verlag 🌐 English ⚖ 757 KB

Guidelines for the use of biochemical ma

Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004)

✍ Yoshiki Nishizawa; Toshitaka Nakamura; Hiroaki Ohta; Kazuhiro Kushida; Itsuo Gor 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 420 KB

The cellular basis of bone remodeling: T

The cellular basis of bone remodeling: The quantum concept reexamined in light of recent advances in the cell biology of bone

✍ A. M. Parfitt 📂 Article 📅 1984 🏛 Springer 🌐 English ⚖ 1009 KB

The effects of oral calcitonin on bone c

The effects of oral calcitonin on bone collagen maturation: implications for bone turnover and quality

✍ M. A. Karsdal; I. Byrjalsen; D. J. Leeming; P. D. Delmas; C. Christiansen 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 157 KB

Effects of denosumab on bone turnover ma

Effects of denosumab on bone turnover markers in postmenopausal osteoporosis

✍ Richard Eastell; Claus Christiansen; Andreas Grauer; Stepan Kutilek; Cesar Liban 📂 Article 📅 2011 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 272 KB 👁 1 views

## Abstract Denosumab, a fully human monoclonal antibody to RANKL, decreases bone remodeling, increases bone density, and reduces fracture risk. This study evaluates the time course and determinants of bone turnover marker (BTM) response during denosumab treatment, the percentage of denosumab‐treat